Literature DB >> 12493342

Definition and epidemiology of overactive bladder.

Alan J Wein1, Eric S Rovner.   

Abstract

The Standardisation Subcommittee of the International Continence Society (ICS) now recognizes overactive bladder (OAB) as a "symptom syndrome suggestive of lower urinary tract dysfunction." It is specifically defined as "urgency, with or without urge incontinence, usually with frequency and nocturia." The ICS definition was not formulated until January 2001 and was not formally approved until September 2001. Therefore, collection and discussion of the epidemiologic characteristics of OAB are somewhat hampered by the different definitions of this condition used by different investigators. Most communications that appeared before 2000 more often described characteristics of incontinence rather than OAB, and the estimates of OAB prevalence within those studies varied significantly. Until recently, little definite epidemiologic information was available on the prevalence and comorbidities of OAB. An important challenge in treating OAB is to increase awareness of this significant problem worldwide and to impress on other specialists and primary care physicians the importance of identifying this clinical problem and managing it in a way that will maximize quality-of-life improvement while minimizing morbidity.

Entities:  

Mesh:

Year:  2002        PMID: 12493342     DOI: 10.1016/s0090-4295(02)01784-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  72 in total

Review 1.  Alternative approaches to sacral nerve stimulation.

Authors:  Kenneth M Peters
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

Review 2.  Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.

Authors:  Michael G Oefelein
Journal:  Drug Saf       Date:  2011-09-01       Impact factor: 5.606

3.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

Review 4.  Improving the tolerability of anticholinergic agents in the treatment of overactive bladder.

Authors:  Roger Dmochowski
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 5.  Lower urinary tract disease: what are we trying to treat and in whom?

Authors:  Jeremy P W Heaton
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

6.  Protective action of intravesical oxybutynin on bladder ultrastructure in rabbits with detrusor overactivity.

Authors:  Hamilto Yamamoto; Paulo Roberto Kawano; Karina Tuma Balasteghin; Carlos Roberto Padovani; João Luiz Amaro
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-10-25

7.  Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.

Authors:  Monique Groen-Wijnberg; Jan van Dijk; Walter Krauwinkel; Virginie Kerbusch; John Meijer; Reiner Tretter; Wenhui Zhang; Marcel van Gelderen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

Review 8.  The puzzle of overactive bladder: controversies, inconsistencies, and insights.

Authors:  Roger R Dmochowski
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-06-27

Review 9.  Trospium chloride in the management of overactive bladder.

Authors:  Eric S Rovner
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms.

Authors:  Fukashi Yamamichi; Katsumi Shigemura; Hosny M Behnsawy; Masuo Yamashita; Toshiro Shirakawa; Masato Fujisawa
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.